Home›Trial›NCT07259330
🔬NCT07259330Phase 1ACTIVE NOT RECRUITING

To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants

Study Summary

This study will evaluate the effects of nirogacestat 100 mg twice daily (BID) on the pharmacokinetics (PK) of a cytochrome P450 (CYP) cocktail.

Conditions
Healthy
Interventions / Drugs
NirogacestatNirogacestat and Cocktail of CYP Specific Probe Substrates
View on ClinicalTrials.gov ↗
Sponsor
SWTX
SpringWorks Therapeutics
Rare Oncology
D40/100
Study Details
Enrollment20 participants
Primary Completion—
Lead SponsorSpringWorks Therapeutics, Inc.
Data Retrieved2026-04-11 04:28:29.597224+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.